Eribulin mesylate

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sarcoma, Soft Tissue

Conditions

Sarcoma, Soft Tissue

Trial Timeline

Mar 1, 2016 → Nov 4, 2018

NCT ID

NCT03058406

About Eribulin mesylate

Eribulin mesylate is a pre-clinical stage product being developed by Eisai for Sarcoma, Soft Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT03058406. Target conditions include Sarcoma, Soft Tissue.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03441360	Phase 2	Completed	Apr 17, 2018	Jan 21, 2022	Relapsed/Refractory Rhabdomyosarcoma
NCT03583944	Approved	Completed	Mar 28, 2018	Jun 28, 2019	Breast Neoplasms
NCT03361436	Phase 1	Active	Mar 19, 2018	Apr 14, 2033	Liposarcoma
NCT03437083	Pre-clinical	Completed	Jan 25, 2018	Jun 30, 2018	Locally Advanced or Metastatic Breast Cancer
NCT03058406	Pre-clinical	Completed	Mar 1, 2016	Nov 4, 2018	Sarcoma, Soft Tissue
NCT02481050	Phase 2	Completed	Jun 16, 2015	Sep 5, 2017	Breast Cancer
NCT02338037	Phase 1	Completed	May 19, 2015	Mar 15, 2024	Metastatic Malignant Neoplasm in the Adult Brain
NCT02171260	Phase 1	Completed	Jul 31, 2014	Jan 28, 2016	Pediatrics
NCT03245112	Pre-clinical	UNKNOWN	Mar 3, 2014	Dec 31, 2017	Metastatic Breast Cancer
NCT01961544	Approved	Completed	Jun 1, 2013	Jul 1, 2015	Breast Neoplasms
NCT01458249	Phase 2	Completed	Nov 1, 2011	Feb 1, 2016	Soft Tissue Sarcoma
NCT01463891	Pre-clinical	Completed	Jul 19, 2011	Nov 27, 2013	Inoperable or Recurrent Breast Cancer
NCT01328249	Phase 2	Completed	Mar 3, 2011	Oct 19, 2017	HER2-normal
NCT01240421	Pre-clinical	Completed	Mar 1, 2011	Nov 1, 2014	Metastatic Breast Cancer
NCT01268150	Phase 2	Completed	Feb 1, 2011	Aug 1, 2013	Locally Recurrent
NCT01269346	Phase 2	Completed	Dec 1, 2010	May 1, 2016	Breast Cancer
NCT01142661	Pre-clinical	Completed	Aug 1, 2010	—	Breast Cancer
NCT01106248	Phase 1	Completed	Mar 1, 2009	—	Advanced Solid Tumor
NCT00965523	Phase 2	Completed	Jan 1, 2008	Jan 1, 2011	Breast Cancer

Competing Products

20 competing products in Sarcoma, Soft Tissue

See all competitors

Product	Company	Stage	Hype Score
Tc99m-tilmanocept	Navidea Biopharmaceuticals	Phase 1	25
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Olaratumab + Doxorubicin + Ifosfamide + Mesna	Eli Lilly	Phase 1	33
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	33
Abemaciclib	Eli Lilly	Phase 2	52
Abemaciclib + Placebo	Eli Lilly	Phase 3	77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acid	Chugai Pharmaceutical	Phase 3	77
PLX3397 + sirolimus	Daiichi Sankyo	Phase 1/2	41
exatecan mesylate	Daiichi Sankyo	Phase 2	52
efatutazone	Daiichi Sankyo	Phase 2	52
soblidotin	Daiichi Sankyo	Phase 2	52
exatecan mesylate	Daiichi Sankyo	Phase 2	52
Linsitinib	Astellas Pharma	Phase 2	52
Fluzoparib+ Dalpiciclib	Sun Pharmaceutical	Phase 2	52
Anlotinib Hydrochloride	Sun Pharmaceutical	Phase 2	52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine	Sun Pharmaceutical	Phase 2	52
irinotecan liposome (II) + temozolomide + fluzoparib	Sun Pharmaceutical	Phase 2	52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV	Eisai	Phase 3	77
Eribulin	Eisai	Phase 2	52
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved